Live Analyst Rating Changes 24636 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Bradley Canino
GUGG

Bradley Canino

Guggenheim
Wall Street Analyst
★★☆☆☆
#2601
on 13Foresight · ranked by our own returns
57%
Success Rate
+3.8%
Average Return
20 of 35 calls profitable · -5.0% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 57% of Bradley Canino's ratings turned a profit when each position was held for 1 year — averaging +3.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

68 Buy 3 Hold 0 Sell
Bradley's Stock Coverage 31 ratings · 2026-08-14
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
JANX
Janux Therapeutics Inc
 Aug 06, 2026 BUY Strong Buy
+190.1% avg upside
21 analysts
$55.00
243.81% Upside
 +0.1% ·
ORIC
Oric Pharmaceuticals
 Aug 03, 2026 BUY Strong Buy
+74.3% avg upside
19 analysts
$18.00
31.22% Upside
 +30.9% ·
KYMR
Kymera Therapeutics
 Jul 28, 2026 BUY Strong Buy
-7.7% avg upside
37 analysts
$135.00
17.91% Upside
 +10.6% ·
SMMT
Summit Therapeutics
 Jul 23, 2026 BUY Strong Buy
+102.5% avg upside
27 analysts
$38.00
171.35% Upside
 -10.9% ·
ANTX
AN2 Therapeutics, Inc.
 Jul 19, 2026 BUY Buy
+47.0% avg upside
8 analysts
$9.00
50.41% Upside
 +24.8% ·
SNDX
Syndax Pharmaceuticals
 Jul 14, 2026 BUY Strong Buy
+83.4% avg upside
27 analysts
$31.00
62.57% Upside
 -17.8% ·
CELC
Celcuity
 Jul 14, 2026 BUY Strong Buy
+40.4% avg upside
16 analysts
$165.00
90.44% Upside
 -17.2% ·
DMRA
Damora Therapeutics
 Jun 15, 2026 BUY Strong Buy
-6.1% avg upside
20 analysts
$40.00
30.08% Upside
 +49.1% ·
OLMA
Olema Pharmaceuticals
 Jun 01, 2026 BUY Strong Buy
+265.5% avg upside
16 analysts
$35.00
233.03% Upside
 -16.4% ·
BCAX
Bicara Therapeutics Inc.
 May 26, 2026 BUY Strong Buy
+34.5% avg upside
15 analysts
$42.00
77.77% Upside
 +10.5% ·
RLAY
Relay Therapeutics
 May 25, 2026 BUY Strong Buy
+8.8% avg upside
21 analysts
$26.00
30.51% Upside
 +40.2% ·
CBIO
Crescent Biopharma
 Apr 29, 2026 BUY Strong Buy
+33.8% avg upside
17 analysts
$35.00
110.43% Upside
 -19.6% ·
TYRA
Tyra Bioscience
 Apr 15, 2026 BUY Strong Buy
+77.8% avg upside
17 analysts
$54.00
115.80% Upside
 -27.7% ·
CGEM
Cullinan Management
 Mar 10, 2026 BUY Strong Buy
+73.8% avg upside
15 analysts
$30.00
52.79% Upside
 +36.4% ·
CGON
CG Oncology, Inc.
 Feb 27, 2026 BUY Strong Buy
+14.7% avg upside
17 analysts
$90.00
20.44% Upside
 +27.6% ·
CCCC
C4 Therapeutics
 Feb 26, 2026 BUY Strong Buy
+337.3% avg upside
19 analysts
$7.00
71.47% Upside
 +52.5% ·
BDTX
Black Diamond Therapeutics
 Dec 03, 2025 HOLD Strong Buy
+607.4% avg upside
12 analysts
 — -24.9% ·
PYXS
Pyxis Oncology
 Sep 03, 2025 BUY Strong Buy
+141.1% avg upside
14 analysts
$5.00
66.13% Upside
 +104.8% ·
KURA
Kura Oncology
 Sep 03, 2025 HOLD Strong Buy
+156.5% avg upside
26 analysts
 — +28.8% ·
ZNTL
Zentalis Pharmaceuticals
 Mar 27, 2025 BUY Buy
+235.9% avg upside
18 analysts
$9.00
116.97% Upside
 +17.3% ·
ALXO
ALX Oncology Holdings
 Mar 07, 2025 HOLD Strong Buy
+825.0% avg upside
11 analysts
$1.50
22.75% Downside
 +108.5% ·
ARVN
Arvinas Holding Company
 Feb 12, 2025 BUY Buy
+217.9% avg upside
28 analysts
$51.00
465.98% Upside
 -34.0% ·
AFMDQ
Affimed
 Jan 09, 2025 HOLD Buy
+14226263.6% avg upside
16 analysts
 — · ·
SRRK
Scholar Rock Holding
 Apr 26, 2021 BUY Strong Buy
+8.4% avg upside
23 analysts
$65.00
22.41% Upside
 -77.7% ·
IMA
ImageneBio
 Apr 26, 2021 BUY Buy
+186.0% avg upside
12 analysts
$30.00
411.09% Upside
 · ·
BCAB
BioAtla
 Apr 26, 2021 BUY Strong Buy
+2676.4% avg upside
13 analysts
$68.00
1870.96% Upside
 · ·
OBX
Obsidian Therapeutics
 Apr 26, 2021 BUY Buy
-49.6% avg upside
9 analysts
$15.00
20.65% Downside
 · ·
MGNX
MacroGenics
 Apr 26, 2021 BUY Buy
+330.9% avg upside
25 analysts
$37.00
806.82% Upside
 -78.5% ·
EXEL
Exelixis
 Mar 30, 2021 BUY Buy
-13.9% avg upside
34 analysts
$30.00
40.80% Downside
 +2.1% ·
ZYME
Zymeworks
 Mar 30, 2021 BUY Strong Buy
+29.0% avg upside
25 analysts
$55.00
113.48% Upside
 -78.6% ·
ASMB
Assembly Biosciences
 Jul 08, 2020 BUY Strong Buy
+12.8% avg upside
10 analysts
$38.00
26.94% Upside
 -85.2% ·
🔒 26 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Bradley Canino — Frequently Asked Questions
How accurate are Bradley Canino's stock ratings?
Based on the calls 13Foresight could measure, about 54% of Bradley's ratings were profitable over a one-year hold, with an average return of +2.2% per rating, or -6.2% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Bradley ranked on 13Foresight?
Bradley Canino is currently ranked #2601 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Bradley cover?
Bradley most recently has ratings on JANX, ORIC, KYMR, SMMT, ANTX, SNDX, CELC, DMRA, OLMA, BCAX, RLAY, CBIO and 19 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.